|
Allele Symbol Allele Name Allele ID |
Msh2tm1Htr targeted mutation 1, Hein Te Riele MGI:1858055 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary |
13 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 30% of homozygous animals developed metastasizing lymphomas of T cell origin, peaking at 2 months of age
|
|
• 30% of homozygous animals developed metastasizing lymphomas of T cell origin, peaking at 2 months of age
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• two-third of mice die by 19.5 weeks
• Background Sensitivity: mice on a pure 129P2/OlaHsd background die sooner than those on a mixed 129P2/OlaHsd and FVB background
|
| N |
• somatic hypermutation rates in memory B cells are normal
|
|
• LPS-stimulated blasting B cells exhibit a 7-fold reduction in switching to IgG3 compared with similarly treated wild-type mice
• however, IgM response to LPS treatment is normal
|
|
• mice exhibit a 61% reduction in total mutation frequency in germinal center B cell compared with wild-type mice
|
|
• following NP-ficcoll or LPS plus IL4 stimulation
|
|
• following NP-ficcoll or LPS stimulation
|
|
• LPS-stimulated blasting B cells exhibit a 7-fold reduction in switching to IgG3 compared with similarly treated wild-type mice
• however, the proportion of B cells that blasted in response to LPS is normal
|
|
• mice that survive beyond 19.5 weeks exhibit a multitude of tumor types (lymphoid, erythroid, intestine, skin, sebaceous gland, brain, intestine, and hereditary nonpolyposis colorectal cancer)
|
|
• all mice that survive beyond 30 weeks develop HNPCC (hereditary nonpolyposis colorectal cancer)
|
|
• in mice that survive beyond 19.5 weeks
|
|
• 80% of mice that die prior to 19.5 weeks of age present with a lymphoid tumor, mostly of T cell origin
|
|
• in 13% of mice that survive beyond 19.5 weeks
|
|
• LPS-stimulated blasting B cells exhibit a 7-fold reduction in switching to IgG3 compared with similarly treated wild-type mice
• however, IgM response to LPS treatment is normal
|
|
• mice exhibit a 61% reduction in total mutation frequency in germinal center B cell compared with wild-type mice
|
|
• following NP-ficcoll or LPS plus IL4 stimulation
|
|
• following NP-ficcoll or LPS stimulation
|
|
• in mice that survive beyond 19.5 weeks
|
|
• in 13% of mice that survive beyond 19.5 weeks
|
|
• all mice that survive beyond 30 weeks develop HNPCC (hereditary nonpolyposis colorectal cancer)
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Lynch syndrome | DOID:3883 |
OMIM:PS120435 |
J:45433 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• two-third of mice die by 30 weeks
• Background Sensitivity: mice on a mixed 129P2/OlaHsd and FVB background die sooner than those on a pure 129P2/OlaHsd background
|
|
• mice that survive beyond 30 weeks exhibit a multitude of tumors types (lymphoid, erythroid, intestine, skin, uterus, mammary gland, lung, intestine, sebaceous gland, and hereditary nonpolyposis colorectal cancer)
|
|
• 62% of mice that survive beyond 30 weeks develop Hereditary Nonpolyposis Colon Cancer (HNPCC) tumors
|
|
• in mice that survive beyond 30 weeks
|
|
• all ENU-treated mice develop lymphomas by 14 weeks of age compared with 25% of similarly treated wild-type mice by 13 and 27 weeks
|
|
• in mice that survive beyond 30 weeks
|
|
• 80% of mice that die prior to 30 weeks of age present with a lymphoid tumor, mostly of T cell origin
• all ENU-treated mice develop lymphomas by 14 weeks of age compared with 25% of similarly treated wild-type mice by 13 and 27 weeks
|
 |
• in mice that survive beyond 30 weeks
|
|
• in mice that survive beyond 30 weeks
|
|
• all ENU-treated mice develop lymphomas by 14 weeks of age compared with 25% of similarly treated wild-type mice by 13 and 27 weeks
|
|
• in mice that survive beyond 30 weeks
|
|
• in mice that survive beyond 30 weeks
|
|
|
• in mice that survive beyond 30 weeks
|
|
• in mice that survive beyond 30 weeks
|
|
• 62% of mice that survive beyond 30 weeks develop Hereditary Nonpolyposis Colon Cancer (HNPCC) tumors
|
|
• in mice that survive beyond 30 weeks
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice die within 100 weeks
|
|
• mice develop more tumors than wild-type mice including lung, liver, mammary gland, skin, uterus, hemangiosarcoma, Schwann cell, teratocarcinoma, osteosarcoma, adrenal gland, and bladder tumors
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 20% of mice die 15 weeks after UVB-irradiation unlike similarly treated wild-type mice
|
|
• 20% of mice die of lymphomas by 20 weeks of age
|
|
• by 52 weeks, 81% of mice develop skin tumors
• 18 weeks after UVB-irradiation mice develop skin tumors compared with 23 weeks for similarly treated wild-type mice
|
|
• 23% of spontaneous skin tumors are papillomas
|
|
• 77% of spontaneous skin tumors are squamous cell carcinomas
|
|
• 20% of mice die of lymphomas by 20 weeks of age
• 15 weeks after UVB-irradiation, mice develop lymphomas unlike similarly treated wild-type mice
|
|
• 15 weeks after UVB-irradiation, mice develop lymphomas unlike similarly treated wild-type mice
• 18 weeks after UVB-irradiation mice develop skin tumors compared with 23 weeks for similarly treated wild-type mice
• UVB-irradiated mice do not remain tumor free as long as similarly treated wild-type mice
|
|
• by 52 weeks, 81% of mice develop skin tumors
• 18 weeks after UVB-irradiation mice develop skin tumors compared with 23 weeks for similarly treated wild-type mice
|
|
• 23% of spontaneous skin tumors are papillomas
|
|
• 77% of spontaneous skin tumors are squamous cell carcinomas
|
|
• 20% of mice die 15 weeks after UVB-irradiation unlike similarly treated wild-type mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice exhibit a reduction in total mutation frequency in germinal center B cell compared with wild-type mice that is similar to that observed in Msh2tm1Htr homozygotes
|
|
• mice exhibit a reduction in total mutation frequency in germinal center B cell compared with wild-type mice that is similar to that observed in Msh2tm1Htr homozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• intranuclear accumulation of mutant huntingtin is delayed 5 months compared to in Htttm5Mem heterozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• survival is reduced 4-fold compared with ApcMin heterozygotes
• all mice die within 5 months
|
|
• mice have an 8-fold increase in intestinal tumor load compared with ApcMin heterozygotes
|
|
• mice have an 8-fold increase in intestinal tumor load compared with ApcMin heterozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• enterocytes of mice treated with MNNG, temozolomide, and cisplatin exhibit reduced apoptosis compared to cells from similarly treated wild-type mice
• decreased induced apoptosis is not affected by O6-benzylguanine treatment
|
|
• enterocytes of mice treated with MNNG, temozolomide, and cisplatin exhibit reduced apoptosis compared to cells from similarly treated wild-type mice
• decreased induced apoptosis is not affected by O6-benzylguanine treatment
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mean life expectancy is 107 days compared with 223 days for Msh2tm1Htr homozygotes
|
|
• fewer than expected mice are identified at weaning
|
|
• in all mice that die
|
|
• in 4 of 5 mice with tumors
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mean life expectancy is 107 days compared with 223 days for Msh2tm1Htr homozygotes
|
|
• fewer than expected mice are identified at weaning
|
|
• in all mice that die
|
|
• in 4 of 5 mice with tumors
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 32% of mice die 15 weeks after UVB-irradiation compared with 3% of similarly treated Xpatm1Tnka homozygotes
|
|
• 18% of mice die of lymphomas by 20 weeks of age
|
|
• in 81% of mice by 52 weeks
|
|
• 9% of spontaneous skin tumors are papillomas
|
|
• 91% of skin tumors are squamous cell carcinomas
• all skin tumors in UVB-treated mice are diagnosed as squamous cell carcinomas
|
|
• 18% of mice die of lymphomas by 20 weeks of age
|
|
• UVB-treated mice develop skin tumors a week earlier than similarly treated Xpatm1Tnka homozygotes
• all UVB-treated mice develop skin tumors, all of which are squamous cell carcinomas, at 10 weeks compared with 20 weeks for similarly treated Xpatm1Tnka homozygotes
|
|
• in 81% of mice by 52 weeks
|
|
• 9% of spontaneous skin tumors are papillomas
|
|
• 91% of skin tumors are squamous cell carcinomas
• all skin tumors in UVB-treated mice are diagnosed as squamous cell carcinomas
|
|
• 32% of mice die 15 weeks after UVB-irradiation compared with 3% of similarly treated Xpatm1Tnka homozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice that survive beyond 30 weeks exhibit a multitude of tumors types (erythroid, intestine, skin, uterus, mammary gland, lung, intestine, and hereditary nonpolyposis colorectal cancer)
|
|
• 80% of mice that survive beyond 30 weeks develop Hereditary Nonpolyposis Colon Cancer (HNPCC) tumors
|
|
• in mice that survive beyond 30 weeks
|
|
• in mice that survive beyond 30 weeks
|
|
|
• in mice that survive beyond 30 weeks
|
|
• in mice that survive beyond 30 weeks
|
|
• in mice that survive beyond 30 weeks
|
|
• in mice that survive beyond 30 weeks
|
|
|
• in mice that survive beyond 30 weeks
|
|
• 80% of mice that survive beyond 30 weeks develop Hereditary Nonpolyposis Colon Cancer (HNPCC) tumors
|
|
• in mice that survive beyond 30 weeks
|
|
• in mice that survive beyond 30 weeks
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Lynch syndrome | DOID:3883 |
OMIM:PS120435 |
J:45433 | |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/09/2024 MGI 6.23 |
|
|
|
||
Analysis Tools